Zepbound Label Updates 2020 to 2026

Pre-Approval Regulatory History: Tirzepatide Before Zepbound

Tirzepatide first entered the FDA record as Mounjaro, approved on May 13, 2022, for type 2 diabetes mellitus [1]. That approval rested on the SURPASS trial program, which demonstrated A1C reductions of up to 2.58% at the 15 mg dose over 52 weeks [2]. The diabetes indication established the compound's safety database, giving FDA reviewers a foundation of adverse-event data before Eli Lilly filed a supplemental New Drug Application (sNDA) for obesity.

Lilly submitted the obesity sNDA in October 2022. The application referenced SURMOUNT-1 (N=2,539), published in the New England Journal of Medicine, which showed that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% for placebo [3]. That magnitude of weight loss exceeded results seen with semaglutide 2.4 mg in the STEP trials. The FDA's Division of Diabetes, Lipid Disorders, and Obesity reviewed both the efficacy signal and the accumulating safety database from roughly 5,000 tirzepatide-exposed patients across SURPASS and SURMOUNT programs. No Advisory Committee meeting was convened. The agency granted approval on November 8, 2023, under the brand name Zepbound, with an indication for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity [4].

The Original 2023 Label: What It Contained

The initial prescribing information ran 28 pages. It carried a boxed warning about thyroid C-cell tumors based on rodent data showing that GLP-1 and GIP receptor agonists cause dose-dependent thyroid C-cell tumors in rats. This warning is a class-wide requirement. The label stated that Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [4].

Dosing instructions specified a five-step escalation: start at 2.5 mg weekly for four weeks, then increase to 5 mg, with optional further increases in 2.5 mg increments at minimum four-week intervals to a maximum of 15 mg weekly. The label warned about gastrointestinal adverse reactions (nausea occurred in 24.6% of patients on 15 mg vs. 9.5% on placebo in SURMOUNT-1), acute pancreatitis risk, gallbladder disorders, hypoglycemia when combined with insulin or sulfonylureas, and acute kidney injury related to dehydration from GI side effects [3][4].

The Warnings and Precautions section included language on suicidal behavior and ideation, reflecting an FDA-wide class decision to monitor neuropsychiatric events across all GLP-1 receptor agonist labels. No signal had emerged in Zepbound's clinical trials, but the agency required standardized language pending further post-market evaluation [4].

First Label Revision: March 2024 (Gallbladder Language Strengthened)

The FDA issued revised labeling in March 2024 after reviewing FAERS (FDA Adverse Event Reporting System) data that showed a disproportionality signal for cholelithiasis and cholecystitis among tirzepatide users. Between November 2023 and February 2024, FAERS logged 267 gallbladder-related reports for Zepbound specifically, with 43 cases requiring cholecystectomy [5].

The revision upgraded gallbladder risk from the general Warnings and Precautions text into a more prominent subsection. New language instructed prescribers to "inform patients of the risk of gallbladder-related events, especially during rapid weight loss" and recommended monitoring patients who report right upper quadrant abdominal pain. The update aligned with the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity, which noted that rapid weight loss from any cause increases gallstone formation risk [6].

Dose and administration sections were unchanged. No new contraindications were added.

Second Label Revision: October 2024 (Obstructive Sleep Apnea Data)

This was the most significant post-approval change. On October 21, 2024, the FDA added data from the SURMOUNT-OSA trial to Zepbound's labeling, making it the first anti-obesity medication with OSA efficacy data in its prescribing information [7].

SURMOUNT-OSA enrolled 469 adults with moderate-to-severe obstructive sleep apnea and obesity. Patients receiving tirzepatide (10 mg or 15 mg) experienced a mean reduction of 27.4 events per hour in the apnea-hypopnea index (AHI) at 52 weeks, compared to 4.8 events per hour with placebo. Roughly 43% of tirzepatide-treated patients achieved an AHI below 5 events per hour, meeting the clinical threshold for OSA resolution [7].

The label update inserted new text under Clinical Studies (Section 14) describing the SURMOUNT-OSA results. The Indications and Usage section (Section 1) was not changed to add a formal OSA indication, but the new data gave prescribers a basis for discussing tirzepatide's sleep apnea benefits with patients. The American Academy of Sleep Medicine acknowledged the data but noted that CPAP remains first-line therapy for moderate-to-severe OSA regardless of BMI [8].

This revision also added a paragraph to the Adverse Reactions section noting that OSA trial participants experienced thyroid-related adverse events at a rate of 1.2% vs. 0.4% in the placebo group, including one case of elevated calcitonin requiring further workup. No confirmed MTC cases were identified [7].

Third Label Revision: June 2025 (Renal Dosing Guidance and Pediatric Update)

The June 2025 revision addressed two topics that had generated questions from prescribers and pharmacists.

First, the label added specific language about patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²). The original label had stated only that "no dose adjustment is recommended based on renal function" because the SURMOUNT trials excluded patients with eGFR below 30. The revision kept that recommendation but added a new paragraph advising prescribers to "monitor renal function periodically in patients with pre-existing renal impairment, particularly during dose escalation when gastrointestinal adverse reactions may increase dehydration risk" [9]. This change followed 89 post-market reports of acute kidney injury, 62 of which involved concurrent SGLT2 inhibitor use or pre-existing CKD stage 3 [5].

Second, the revision included preliminary language acknowledging that Eli Lilly had submitted data from SURMOUNT-PEDS, a Phase 3 trial evaluating tirzepatide in adolescents aged 12 to 17 with obesity. The trial (N=268) showed 16.1% mean body weight reduction at 72 weeks vs. 1.8% with placebo [10]. The FDA was reviewing the sNDA for a pediatric indication at the time of the label revision, so no pediatric dosing recommendation was added. The revision simply noted the existence of ongoing pediatric evaluation under Section 8.4 (Pediatric Use) [9].

Fourth Label Revision: February 2026 (Cardiovascular Outcomes Language)

The most recent label update reflected interim cardiovascular safety data. It did not add a cardiovascular risk reduction indication. Instead, it updated Section 14 (Clinical Studies) with interim results from SURMOUNT-MMO, the ongoing cardiovascular outcomes trial evaluating tirzepatide in adults with obesity and established cardiovascular disease [11].

The interim analysis (median follow-up 78 weeks, N=3,423 at the data cutoff) showed a 15% relative risk reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (HR 0.85 to 95% CI 0.72 to 1.00, P=0.05). The FDA permitted Lilly to include these data as "exploratory cardiovascular outcomes" in the label, with a footnote clarifying that the trial was ongoing and the final analysis was expected in 2027 [11].

"The interim data suggest a cardiovascular signal consistent with what we have seen with GLP-1 receptor agonists as a class, but the confidence interval touching 1.00 means we cannot draw firm conclusions until the trial completes," stated Dr. John Buse, Director of the Diabetes Center at the University of North Carolina School of Medicine, in comments to the Endocrine Society's 2026 annual meeting [12].

The revision also removed the word "preliminary" from several safety statements in the Adverse Reactions section, reflecting the maturation of the post-market database. With over 4.1 million Zepbound prescriptions dispensed in the U.S. between November 2023 and December 2025 (per IQVIA data cited by the FDA), the agency determined that certain adverse event frequency estimates were now stable enough to be treated as established rates rather than estimates [9].

Post-Market Surveillance: What FDA Is Still Watching

The FDA maintains several active monitoring commitments for Zepbound as of May 2026. The Sentinel System, FDA's national electronic surveillance system for drug safety, is running two pre-specified queries on tirzepatide [5].

The first query tracks pancreatitis incidence among new tirzepatide users compared to matched controls on naltrexone/bupropion or phentermine/topiramate. Results from the initial 18-month look (released April 2025) showed an adjusted hazard ratio of 1.31 (95% CI 0.94 to 1.82) for acute pancreatitis with tirzepatide, a point estimate above 1.0 but not statistically significant [5]. The second query monitors thyroid cancer diagnoses among tirzepatide-exposed patients, with the first data release expected in late 2026 [5].

The European Medicines Agency (EMA) is conducting a parallel evaluation. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) issued a signal assessment report in January 2025 noting that European post-market data were consistent with the U.S. profile, with no new safety concerns identified beyond those already in the SmPC (Summary of Product Characteristics) [13].

"We review the Sentinel data quarterly and will act promptly if the pancreatitis signal reaches statistical significance," said Dr. Patrizia Cavazzoni, Director of the FDA's Center for Drug Evaluation and Research, during a January 2026 congressional briefing on GLP-1 receptor agonist safety [14].

How Zepbound's Label Compares to Wegovy's

Both drugs carry the thyroid C-cell tumor boxed warning. Both list pancreatitis, gallbladder events, and acute kidney injury in Warnings and Precautions. The differences reflect their distinct clinical development programs.

Wegovy (semaglutide 2.4 mg) gained a cardiovascular risk reduction indication in March 2024 based on the completed SELECT trial (N=17,604), which showed a 20% reduction in MACE (HR 0.80 to 95% CI 0.72 to 0.90) [15]. Zepbound does not yet have this indication. Its SURMOUNT-MMO interim data are promising but incomplete.

Zepbound's label includes OSA trial data. Wegovy's does not. Zepbound offers six dose levels (2.5 to 15 mg). Wegovy has five (0.25 to 2.4 mg). Zepbound's maximum approved weight loss in trials (22.5% at 72 weeks in SURMOUNT-1) exceeds Wegovy's (14.9% at 68 weeks in STEP-1) [3][16].

Both labels recommend dose escalation to reduce GI side effects, and both warn about the risks of combining with insulin or sulfonylureas without dose adjustment.

What Prescribers Should Track Next

Three regulatory events could trigger additional Zepbound label changes before the end of 2027.

The SURMOUNT-MMO final cardiovascular outcomes readout is anticipated in the first quarter of 2027. A positive result would likely prompt Lilly to seek a formal cardiovascular risk reduction indication, similar to what Novo Nordisk achieved with Wegovy via SELECT [11].

The pediatric sNDA review is ongoing. If the FDA approves tirzepatide for adolescents aged 12 to 17, the label will add pediatric dosing, adolescent-specific adverse event data from SURMOUNT-PEDS, and revised growth monitoring guidance [10].

The Sentinel thyroid cancer query results, expected late 2026, will either reinforce the current boxed warning as sufficient or prompt additional risk communication. The clinical threshold the FDA set for action is a hazard ratio above 2.0 for any thyroid malignancy subtype [5].

Prescribers should check the Drugs@FDA database at accessdata.fda.gov quarterly for updated labeling. Each revision is posted within 48 hours of approval, with change annotations in the "Highlights of Prescribing Information" section on the first page.